Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma
Cancer Research and Treatment · 2024
DOI: 10.4143/crt.2023.869 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Sang Eun Yoon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Circulating Tumor DNA, Mutation, Biomarkers, Tumor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Purpose
The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear.Materials and Methods We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes.
Results
Forty samples from patients receiving rituximab-containing immunochemotherapy were analyzed. Baseline sequencing detected mutations in all cases, with the major detected mutations being KMT2C (50%), CREBBP (45%), and KMT2D (45%). The concentration of ctDNA and tumor mutation burden showed a significant association with survival outcome. In particular, the presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them. Longitudinal analysis of ctDNA using serially collected plasma samples showed an association between persistence or reappearance of ctDNA mutations and disease relapse or progression.
Conclusion
Analysis of ctDNA mutations in plasma at diagnosis might help predict outcome of disease, while analysis during follow-up may help to monitor disease status of patients with advanced FL. However, the feasibility of ctDNA measurement must be improved in order for it to become an appropriate and clinically relevant test in FL patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Geninus Inc., Seoul, Korea.
- Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Yoon, S. E., Shin, S. H., Nam, D. K., Cho, J., Kim, W. S., & Kim, S. J. (2024). Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma. Cancer Research and Treatment. https://doi.org/10.4143/crt.2023.869
Vancouver
Yoon SE, Shin SH, Nam DK, Cho J, Kim WS, Kim SJ. Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma. Cancer Research and Treatment. 2024. doi:10.4143/crt.2023.869
BibTeX
@article{Yoon2024,
author = {Yoon, Sang Eun and Shin, Seung-Ho and Nam, Dae Keun and Cho, Junhun and Kim, Won Seog and Kim, Seok Jin},
title = {Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma},
journal = {Cancer Research and Treatment},
year = {2024},
doi = {10.4143/crt.2023.869}
}
EUVIMED